Fortune Business Insights predicts the global immunoglobulin market size was USD 16.24 billion in 2023 and is projected to grow from USD 17.58 billion in 2024 to USD 35.85 billion by 2032, exhibiting a CAGR of 9.3% during the forecast period (2024-2032). All information related to the market is provided in the report, titled, “Intravenous Immunoglobulins Market Size, Share and Global Trend by Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025”. The rising incidence of immunodeficiency diseases in both emerging and developed nations is propelling growth of the intravenous immunoglobulins market.

As per the report, the global intravenous immunoglobulins market is expected to be dominated by the primary immunodeficiency segment with respect to segmentation by indication. In 2017, the primary immunodeficiency segment held 28.6% of the overall intravenous immunohlobulins market share. This is owing to the increasing prevalence of primary immunodeficiency that there is rise in demand for immunoglobulins. Beside this, the assending focus on treating primary immunodeficiency is further expected to boost the market. Owing to the factors mentioned above, this segment is anticipated to continue dominating the market in the forecast duration as well.

Increasing Adoption of Immunoglobulins to Help Asia Pacific Register Fastest Growth

According to the report, the global intravenous immunoglobulin market was dominated by North America with a market value of US$ 5,587.4 Mn in 2017. The region is likley to remain dominant through the forecast period as well due to the presence of first line treatment for critical immune disorders. Other factors boosting the market in the region are rising number of patients and efficient results of the intravenous immunoglobulin treatment.

On the other side, the market in Asia Pacific is anticipated to grpow at faster rate in the coming years on account of the rise in awareness about the treatment option avaiulable for immunologic deficiencies. In addition to this, the rise in adoption and expenditure of immunoglobulins in economies such as Japan, China,and Indiais anticipated to boost the market in the region.

Increasing Cases of Hypogammaglobulinemia and Other Chronic Diseases to Boost Global Market

The increasing geriatric population and their susceptibility towards various health issues are boosting the global intravenoius immunogulobulin market. The increasing number of hemophilic patients around the world is adding to the growth of the market. This, coupoled with the prevailing number of diseases such as hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), and others is also fueling the demand for immunoglobuolin treatment, ultimately boosting the market.

On the flipside, the market may face challenges in terms of strict government rules and regulations with regard to the use of intravenous immunoglobulin products. In addition to this, the high risks associated with the use of these products may result in side effects and this, may further repress the growth of the market affecting its revenue globally.

Grifols, S.A., Leading Market with Better Product Offerings

Analysts at Fortune Business Insights foresees the Grifols, S.A., to emerge as the dominant player in the global market for intravenous immunoglobulin market. This is because this company was leading the market in the year 2017 as well, all because oftheir product offerings and the usual route of administration, whioch ultimately dominated a considerate proportion of share ion the market. Besides this, Grifols, S.A., accounts for largest revenues from well developed regions namely Europe and North America.

Other companies operating in the global iontravenous immunoglobulin market are Bio Products Laboratory Ltd., Kedrion S.p.A, Grifols, S.A., Biotest AG, China Biologic Products Holdings, Inc., Octapharma, and CSL Behring.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower, Baner-Mahalunge Road,
Baner, Pune-411045, Maharashtra, India.

Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]

Fortune Business Insights™

Linkedin | Twitter | Blogs

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]